Highlights in poststroke care from ISC 2026 include benefits of asundexian, promise of an investigational revascularization ...

Perioperative morbidity and mortality were reduced with off-pump vs on-pump coronary artery bypass grafting, though survival ...

That's a big leap over a relatively short period, and the trend offers a significant opportunity for medical device makers, ...

BD (NYSE: BDX) announced today that it received CE mark approval for its Revello vascular covered stent system.

has been cited by the following article: ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has obtained ...

These findings were published in August 2025, in Cardiovascular Revascularization Medicine.

First-in-class, once-daily oral non-statin therapy now available by prescription across CanadaAddresses a significant unmet need for over half a million ...

Abstract Background: Evidence is limited on factors driving target lesion revascularization (TLR) after drug-coated balloon (DCB) treatment for de novo coronary lesions. This study evaluated the ...

Amid late-breaking coronary, structural, and endovascular trials will be a keynote from President Biden, and more.

More inclusive research on bleeding could enable better care for medically managed patients, not just those who get PCI.

The Revello™ Vascular Covered Stent is designed to combine the flexibility of a nitinol self-expanding stent with the radial ...